ClinicalTrials.gg
CompletedNCT01709864Updated Mar 4, 2015Results posted

NVA237 Versus Placebo 12-week Efficacy Study

A Phase 3 interventional study of NVA237 and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Novartis Pharmaceuticals. Completed at 54 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2015-03-04.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
440
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
24th of 73
440 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
29th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 24th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 29th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe. The efficacy and safety of the drug will be tested against a placebo treatment.

The primary criterion to assess efficacy will be the difference between the serial lung function measurements of patients who have been treated for 12 weeks with NVA237 versus those that have received placebo treatment for 12 weeks. A serial lung function measurement (FEV1 testing) will be conducted and the "area under the curve" will be the measure for the ability to breathe.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease

Keywords

  • Anticholinergic
  • Antimuscarinic
  • Chronic Obstructive Airway Disease
  • Chronic Obstructive Lung Disease
  • Chronic Obstructive Pulmonary Disease
  • COPD
  • LAMA
  • Lung Disease
  • Lung Diseases, Obstructive
  • Lung Function
  • Muscarinic receptor antagonist
  • Pulmonary Disease, Chronic Obstructive
  • Respiratory Tract Diseases
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with stable, symptomatic (COPD) with airflow obstruction of level 2 and 3 according to the current Global initiative for chronic Obstructive Lung Disease (GOLD) strategy (2011).
  2. Patients with (FEV1) ≥ 30% and \<80 % of the predicted normal, and FEV1/ Forced Vital Capacity (FVC) \< 0.70 when measured 45 min after the inhalation of 84 µg ipratropium bromide.
  3. Current or ex-smokers with at least 10 cigarette pack years smoking history.

Exclusion criteria

Exclusion criteria:

  1. Patients with a history of long syndrome, with a prolonged QTc measured during screening, or patients who have a abnormality at screening.
  2. History of of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or .
  3. Pregnant or nursing (lactating) women. Women of unless using an effective method of .
  4. Patients who in the judgment of the investigator, would be at potential risk if enrolled into the study.
  5. Patients who have a clinically significant concomitant disease at screening, including but not limited to clinically significant laboratory abnormalities, clinically significant renal, cardiovascular, neurological, endocrine, immunological, psychiatric, gastrointestinal, hepatic, or hematological abnormalities, or with uncontrolled diabetes, which could interfere with the assessment of the efficacy and safety of the study treatment.
  6. Patients with a (BMI) of more than 40 kg/m2.
  7. Patients for treatment with, or having a history of reactions/ to anticholinergic agents, long and short acting beta-2 agonists, or sympathomimetic amines.
  8. Patients with any history of asthma, with onset of symptoms prior to age 40 years, or patients with a high blood eosinophil count during screening.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
440 participants (actual)

Study arms

  • Experimental
    NVA237

    NVA237 will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks

    Drug: NVA237

  • Placebo comparator
    Placebo

    Placebo will be inhaled from a single-dose dry powder inhaler for a period of 12 weeks.

    Drug: Placebo

Interventions

  • DrugNVA237

    NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.

  • DrugPlacebo

    Placebo powder for inhalation in single-dose capsules (matching those for NVA237).

06

What researchers measure

Primary outcomes

  1. Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) at week 12 of treatment. Serial lung function measurements are taken at various time points following dosing at week 12 to calculate the AUC.

    Time frame: 12 weeks

Secondary outcomes

  1. Change From Baseline in Trough FEV1 and Pre-dose Trough FEV1 by Visit

    Trough Forced Expiratory Volume in one second (FEV1) is the mean of FEV1 at 23h 15min and 23h 45min after the morning dose of the previous day. Pre-dose trough FEV1 is the mean of FEV1 at -45min and -15min before morning dose

    Time frame: Day 2, 86 (trough) Day 15, 29, 57, 85 (pre-dose trough)

  2. Change From Baseline in FEV1 AUC (0-12H) at Day 1 and FEV1 AUC (0-4h), AUC (4-8h), AUC (8-12h) at Day 1 and Week 12 (Day 85)

    The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans within the overall serial measurement post dosing (FEV1 AUCs Time Spans), at day 1 and at week 12 of treatment. Serial lung function measurements are taken at various time points post dosing on day 1 and at week 12 to calculate the AUC for these different time spans.

    Time frame: Day 1 and Week 12 (Day 85)

  3. Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire

    The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a 50 item scale assessing symptoms, patient activities and impact of the disease. Scores range from 0 to 100 units, with higher scores indicating more limitations. The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically meaningful improvement (MCID) in SGRQ is defined as a decrease of 4 or more units of the SGRQ scale in the total score, as compared to baseline (change from baseline).

    Time frame: Week 12

  4. Percentage of Participants With a Clinically Important Improvement of >=4units in the SGRQ Total Score at Week 12

    The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically significant improvement in SGRQ is defined as less than or equal to -4 change from baseline.

    Time frame: Week 12

  5. Breathlessness Assessed by Transition Dyspnea Index (TDI) Focal Score at Week 12

    Breathlessness at week 12 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Patients are considered to have clinically significant improvement with the TDI score change versus BDI being equal to or greater than 1. TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.

    Time frame: Week 12

  6. Change From Baseline of Daily Symptom Scores

    Patients reported symptoms using an electronic diary.The diary has 9 symptom questions each am and each pm. Each question can be answered w/1 of 4 pre-defined answers, with a unit value of 0-3, 0 is least \& 3 is most severe symptom.Symptom scores are calculated as the mean of combined daily symptom scores(combined from am \& pm)for each patient over 12 weeks. The baseline is calculated from the run-in epoch prior to randomization.The change from baseline is in LS mean daily symptom scores over the 12 weeks. If the mean score over the 12 weeks is lower than the baseline, result is (-).A neg. result indicates an improvement in COPD symptom severity. Patients may have met the min. response requirements for the night scores(am questions),but not for the day scores(pm questions)or vice versa, the # of patients analyzed can vary between both day \& night scores. Therefore, the # of patients analyzed for the combined daily symptom score can vary from the #s for individual day \& night scores.

    Time frame: 12 weeks

  7. Change From Baseline of Morning and Nighttime Symptom Scores at Week 12

    Patients reported symptoms using an electronic diary.The diary has 9 symptom questions each am \& each pm.Each question can be answered w/1 of 4 pre-defined answers,with a unit value of 0-3, 0 is least \& 3 is most severe symptom.Symptom scores are calculated as the mean of the symptom scores(either the score assessed in am for the previous 12 hrs-referred to as nighttime scores,or the score assessed in pm for the previous 12 hrs-referred to as the daytime symptom score) for each patient over 12 weeks.The baseline is calculated from the run-in epoch prior to randomization.The change from baseline is in LS mean daily symptom scores over the 12 weeks. If the mean score over the 12 weeks is lower than the baseline, result is (-).A neg. result indicates an improvement in COPD symptom severity. the # of patients analyzed can vary between both day \& night scores. Therefore, the # of patients analyzed for the combined daily symptom score can vary from the #s for individual day \& night scores.

    Time frame: 12 weeks

  8. Percentage of Nights With "no Nighttime Awakenings"

    Patients are reporting symptoms by using an electronic diary. A night with "no nighttime awakening" is defined from diary data as any night where the patient did not wake up due to symptoms. Percentage of no nighttime awakenings from Baseline up to 12 weeks.

    Time frame: from Baseline up to 12 weeks

  9. Percentage of Days With "no Daytime Symptoms"

    Patients are reporting symptoms by using an electronic diary. A day with "no daytime symptoms" is defined from diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum, and no feeling of breathlessness (other than when running) during the past approximately 12 hours. The percentage of days is calculated by the number of days with no daytime symptoms/total number of days with evaluable data X 100.

    Time frame: from Baseline up to 12 weeks

  10. Percentage of "Days Able to Perform Usual Daily Activities"

    Patients are reporting symptoms by using an electronic diary. A "day able to perform usual daily activities" is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms.

    Time frame: from Baseline up to 12 weeks

  11. The Average Number of Puffs of Rescue Medication Per Day

    Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the mean daily number of puffs used per patient over the 12 weeks treatment period.

    Time frame: baseline and 12 weeks

  12. Percentage of Days Without Rescue Medication Use

    Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the percentage of days without usage of rescue medication over the 12 weeks treatment period. The baseline is calculated from the run-in epoch prior to randomization.

    Time frame: 12 weeks

  13. Change From Baseline of Forced Vital Capacity (FVC) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)

    The Forced Vital Capacity (FVC) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed.

    Time frame: Baseline, Day 1 and Week 12 (Day 85)

  14. Change From Baseline of Forced Expiratory Volume in One Second (FEV1) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)

    The Forced Expiratory Volume in one second (FEV1) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed.

    Time frame: Baseline, Day 1 and Week 12 (Day 85)

07

Results

Posted Feb 12, 2015

Participant flow

Participant flow — Overall Study
MilestoneNVA237Placebo
Started222219
Full analysis set (fas)222216
Per protocol set (pps)204201
Completed215208
Not completed711
Withdrew: Physician decision01
Withdrew: Subject/guardian decision56
Withdrew: Lost to follow-up10
Withdrew: Non-compliance with study treatment11
Withdrew: Adverse event02
Withdrew: Death01

Outcome measures

PrimaryChange From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) post dosing (FEV1 AUC) at week 12 of treatment. Serial lung function measurements are taken at various time points following dosing at week 12 to calculate the AUC.

Time frame:
12 weeks
Reported as:
Least squares mean · liters*hr
Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing
liters*hrNVA237Placebo
Change From Baseline of Standardized Area Under the Curve (AUC) for Forced Expiratory Volume in One Second (FEV1) Post Dosing0.125 ± 0.0162-0.014 ± 0.0165
SecondaryChange From Baseline in Trough FEV1 and Pre-dose Trough FEV1 by Visit

Trough Forced Expiratory Volume in one second (FEV1) is the mean of FEV1 at 23h 15min and 23h 45min after the morning dose of the previous day. Pre-dose trough FEV1 is the mean of FEV1 at -45min and -15min before morning dose

Time frame:
Day 2, 86 (trough) Day 15, 29, 57, 85 (pre-dose trough)
Reported as:
Least squares mean · liters
Change From Baseline in Trough FEV1 and Pre-dose Trough FEV1 by Visit
litersNVA237Placebo
Trough FEV1 Day 2 (n=218, n=214)0.141 ± 0.01240.025 ± 0.0122
Trough FEV1 Day 86 (n=218, n=214)0.123 ± 0.01710.007 ± 0.0173
Pre-dose Trough FEV1 Day 15 (n=217, n=208)0.112 ± 0.0135-0.002 ± 0.0135
Pre-dose Trough FEV1 Day 29 (n=217, n=208)0.0105 ± 0.0137-0.005 ± 0.0136
Pre-dose Trough FEV1 Day 57 (n=217, n=208)0.0106 ± 0.0156-0.006 ± 0.0157
Pre-dose Trough FEV1 Day 85 (n=217, n=208)0.090 ± 0.0155-0.029 ± 0.0157
SecondaryChange From Baseline in FEV1 AUC (0-12H) at Day 1 and FEV1 AUC (0-4h), AUC (4-8h), AUC (8-12h) at Day 1 and Week 12 (Day 85)

The standardized Area Under the Curve (AUC) for Forced Expiratory Volume in one second (FEV1) is assessed for different time spans within the overall serial measurement post dosing (FEV1 AUCs Time Spans), at day 1 and at week 12 of treatment. Serial lung function measurements are taken at various time points post dosing on day 1 and at week 12 to calculate the AUC for these different time spans.

Time frame:
Day 1 and Week 12 (Day 85)
Reported as:
Least squares mean · liters*hr
Change From Baseline in FEV1 AUC (0-12H) at Day 1 and FEV1 AUC (0-4h), AUC (4-8h), AUC (8-12h) at Day 1 and Week 12 (Day 85)
liters*hrNVA237Placebo
FEV1, AUC 0-12h Day 1 (n=222, n=216)0.140 ± 0.0108-0.001 ± 0.0106
FEV1, AUC 0-4h Day 1 (n=222, n=216)0.174 ± 0.01030.021 ± 0.0101
FEV1, AUC 0-4h Day 85 (n=222, n=216)0.171 ± 0.01630.001 ± 0.0167
FEV1, AUC 4-8h Day 1 (n=222, n=215)0.138 ± 0.01230.001 ± 0.0121
FEV1, AUC 4-8h Day 85 (n=222, n=215)0.115 ± 0.0172-0.017 ± 0.0174
FEV1, AUC 8-12h Day 1 (n=222, n=215)0.102 ± 0.0122-0.037 ± 0.0120
FEV1, AUC 8-12h Day 85 (n=222, n=215)0.074 ± 0.0166-0.034 ± 0.0168
SecondaryChange From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire

The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The SGRQ is a 50 item scale assessing symptoms, patient activities and impact of the disease. Scores range from 0 to 100 units, with higher scores indicating more limitations. The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically meaningful improvement (MCID) in SGRQ is defined as a decrease of 4 or more units of the SGRQ scale in the total score, as compared to baseline (change from baseline).

Time frame:
Week 12
Reported as:
Least squares mean · score
Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire
scoreNVA237Placebo
Change From Baseline in the Health Status Assessed by St. George's Respiratory Questionnaire-4.4 ± 0.96-1.7 ± 0.96
SecondaryPercentage of Participants With a Clinically Important Improvement of >=4units in the SGRQ Total Score at Week 12

The health status, as reported by the patients, is assessed using the St. George's Respiratory Questionnaire (SGRQ). The assessment is based on total score as well as the percentage of patients with clinically significant improvement at week 12 versus day 1. A clinically significant improvement in SGRQ is defined as less than or equal to -4 change from baseline.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With a Clinically Important Improvement of >=4units in the SGRQ Total Score at Week 12
percentage of participantsNVA237Placebo
Percentage of Participants With a Clinically Important Improvement of >=4units in the SGRQ Total Score at Week 1249.040.6
SecondaryBreathlessness Assessed by Transition Dyspnea Index (TDI) Focal Score at Week 12

Breathlessness at week 12 is measured using the Transition Dyspnea Index (TDI). On day 1, breathlessness is assessed by the Baseline Dyspnea Index (BDI). Patients are considered to have clinically significant improvement with the TDI score change versus BDI being equal to or greater than 1. TDI focal score is based on three domains: functional impairment, magnitude of task and magnitude of effort. Each domain is scored from -3 (major deterioration) to 3 (major improvement) to give an overall TDI focal score of -9 to 9. Higher numbers indicate a better score.

Time frame:
Week 12
Reported as:
Least squares mean · scores on a scale
Breathlessness Assessed by Transition Dyspnea Index (TDI) Focal Score at Week 12
scores on a scaleNVA237Placebo
Breathlessness Assessed by Transition Dyspnea Index (TDI) Focal Score at Week 121.46 ± 0.2890.54 ± 0.286
SecondaryChange From Baseline of Daily Symptom Scores

Patients reported symptoms using an electronic diary.The diary has 9 symptom questions each am and each pm. Each question can be answered w/1 of 4 pre-defined answers, with a unit value of 0-3, 0 is least \& 3 is most severe symptom.Symptom scores are calculated as the mean of combined daily symptom scores(combined from am \& pm)for each patient over 12 weeks. The baseline is calculated from the run-in epoch prior to randomization.The change from baseline is in LS mean daily symptom scores over the 12 weeks. If the mean score over the 12 weeks is lower than the baseline, result is (-).A neg. result indicates an improvement in COPD symptom severity. Patients may have met the min. response requirements for the night scores(am questions),but not for the day scores(pm questions)or vice versa, the # of patients analyzed can vary between both day \& night scores. Therefore, the # of patients analyzed for the combined daily symptom score can vary from the #s for individual day \& night scores.

Time frame:
12 weeks
Reported as:
Least squares mean · Score
Change From Baseline of Daily Symptom Scores
ScoreNVA237Placebo
Change From Baseline of Daily Symptom Scores-1.39 ± 0.139-1.01 ± 0.135
SecondaryChange From Baseline of Morning and Nighttime Symptom Scores at Week 12

Patients reported symptoms using an electronic diary.The diary has 9 symptom questions each am \& each pm.Each question can be answered w/1 of 4 pre-defined answers,with a unit value of 0-3, 0 is least \& 3 is most severe symptom.Symptom scores are calculated as the mean of the symptom scores(either the score assessed in am for the previous 12 hrs-referred to as nighttime scores,or the score assessed in pm for the previous 12 hrs-referred to as the daytime symptom score) for each patient over 12 weeks.The baseline is calculated from the run-in epoch prior to randomization.The change from baseline is in LS mean daily symptom scores over the 12 weeks. If the mean score over the 12 weeks is lower than the baseline, result is (-).A neg. result indicates an improvement in COPD symptom severity. the # of patients analyzed can vary between both day \& night scores. Therefore, the # of patients analyzed for the combined daily symptom score can vary from the #s for individual day \& night scores.

Time frame:
12 weeks
Reported as:
Least squares mean · score
Change From Baseline of Morning and Nighttime Symptom Scores at Week 12
scoreNVA237Placebo
Daytime total symptom score (n=208,202)-1.14 ± 0.133-0.73 ± 0.130
nighttime total symptom score (n=207,202)-1.22 ± 0.143-0.95 ± 0.139
SecondaryPercentage of Nights With "no Nighttime Awakenings"

Patients are reporting symptoms by using an electronic diary. A night with "no nighttime awakening" is defined from diary data as any night where the patient did not wake up due to symptoms. Percentage of no nighttime awakenings from Baseline up to 12 weeks.

Time frame:
from Baseline up to 12 weeks
Reported as:
Least squares mean · percentage of nights
Percentage of Nights With "no Nighttime Awakenings"
percentage of nightsNVA237Placebo
Percentage of Nights With "no Nighttime Awakenings"13.3 ± 2.0011.3 ± 1.97
SecondaryPercentage of Days With "no Daytime Symptoms"

Patients are reporting symptoms by using an electronic diary. A day with "no daytime symptoms" is defined from diary data as any day where the patient has recorded in the evening no cough, no wheeze, no production of sputum, and no feeling of breathlessness (other than when running) during the past approximately 12 hours. The percentage of days is calculated by the number of days with no daytime symptoms/total number of days with evaluable data X 100.

Time frame:
from Baseline up to 12 weeks
Reported as:
Least squares mean · percentage of days
Percentage of Days With "no Daytime Symptoms"
percentage of daysNVA237Placebo
Percentage of Days With "no Daytime Symptoms"5.1 ± 1.652.5 ± 1.62
SecondaryPercentage of "Days Able to Perform Usual Daily Activities"

Patients are reporting symptoms by using an electronic diary. A "day able to perform usual daily activities" is defined from diary data as any day where the patient was not prevented from performing their usual daily activities due to respiratory symptoms.

Time frame:
from Baseline up to 12 weeks
Reported as:
Least squares mean · pecentage of days
Percentage of "Days Able to Perform Usual Daily Activities"
pecentage of daysNVA237Placebo
Percentage of "Days Able to Perform Usual Daily Activities"8.6 ± 2.201.8 ± 2.15
SecondaryThe Average Number of Puffs of Rescue Medication Per Day

Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the mean daily number of puffs used per patient over the 12 weeks treatment period.

Time frame:
baseline and 12 weeks
Reported as:
Least squares mean · number of puffs
The Average Number of Puffs of Rescue Medication Per Day
number of puffsNVA237Placebo
The Average Number of Puffs of Rescue Medication Per Day-1.63 ± 0.180-0.86 ± 0.177
SecondaryPercentage of Days Without Rescue Medication Use

Patients report the number of puffs of rescue medication (salbutamol / albuterol) using an electronic diary. The use of rescue medication is analyzed as the percentage of days without usage of rescue medication over the 12 weeks treatment period. The baseline is calculated from the run-in epoch prior to randomization.

Time frame:
12 weeks
Reported as:
Least squares mean · percentage of days
Percentage of Days Without Rescue Medication Use
percentage of daysNVA237Placebo
Percentage of Days Without Rescue Medication Use16.6 ± 2.3710.5 ± 2.31
SecondaryChange From Baseline of Forced Vital Capacity (FVC) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)

The Forced Vital Capacity (FVC) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed.

Time frame:
Baseline, Day 1 and Week 12 (Day 85)
Reported as:
Least squares mean · liters
Change From Baseline of Forced Vital Capacity (FVC) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)
litersNVA237Placebo
DAY 1/ 5 min (n=221, 214)0.175 ± 0.01520.037 ± 0.0152
DAY 1/ 15 min (n=222, 216)0.265 ± 0.01810.044 ± 0.0180
DAY 1/ 1h (n=222, 216)0.318 ± 0.02070.032 ± 0.0205
DAY 1/ 2h (n=221, 216)0.351 ± 0.02160.071 ± 0.0213
DAY 1/ 4h (n=220, 213)0.290 ± 0.02350.067 ± 0.0231
DAY 1/ 6h (n=221, 214)0.252 ± 0.02350.022 ± 0.0234
DAY 1/ 8h (n=220, 214)0.192 ± 0.0221-0.009 ± 0.0220
DAY 1/ 11h 55min (n=216, 207)0.152 ± 0.0234-0.030 ± 0.0235
DAY 85/ -45 min (n=217, 208)0.162 ± 0.0289-0.043 ± 0.0296
DAY 85/ -15 min (n=216, 208)0.156 ± 0.0283-0.017 ± 0.0287
DAY 85/ 5 min (n=221, 214)0.184 ± 0.0282-0.007 ± 0.0287
DAY 85/ 15 min (n=222, 216)0.263 ± 0.0288-0.003 ± 0.0294
DAY 85/ 1h (n=222, 216)0.258 ± 0.02970.004 ± 0.0302
DAY 85/ 2h (n=221, 216)0.277 ± 0.02990.033 ± 0.0307
DAY 85/ 4h (n=220, 213)0.215 ± 0.03170.076 ± 0.0321
DAY 85/ 6h (n=221, 214)0.199 ± 0.0304-0.015 ± 0.0305
DAY 85/ 8h (n=220, 214)0.128 ± 0.0303-0.023 ± 0.0305
DAY 85/ 11h 55min (n=216, 207)0.110 ± 0.0286-0.006 ± 0.0288
SecondaryChange From Baseline of Forced Expiratory Volume in One Second (FEV1) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)

The Forced Expiratory Volume in one second (FEV1) assessments for all individual time points of the serial measurements on day 1 and at week 12 are analyzed.

Time frame:
Baseline, Day 1 and Week 12 (Day 85)
Reported as:
Least squares mean · liters
Change From Baseline of Forced Expiratory Volume in One Second (FEV1) at All Individual Timepoints at Day 1 and at Week 12 (Day 85)
litersNVA237Placebo
DAY 1/ 5 min (n=221, 214)0.074 ± 0.00750.015 ± 0.0074
DAY 1/ 15 min (n=222, 216)0.129 ± 0.00850.015 ± 0.0084
DAY 1/ 1h (n=222, 216)0.176 ± 0.01080.008 ± 0.0106
DAY 1/ 2h (n=221, 216)0.198 ± 0.01200.031 ± 0.0118
DAY 1/ 4h (n=220, 213)0.168 ± 0.01320.028 ± 0.0129
DAY 1/ 6h (n=221, 214)0.132 ± 0.01350.000 ± 0.0134
DAY 1/ 8h (n=220, 214)0.113 ± 0.0129-0.022 ± 0.0128
DAY 1/ 11h 55min (n=216, 207)0.083 ± 0.0131-0.046 ± 0.0131
DAY 85/ -45 min (n=217, 208)0.092 ± 0.0154-0.040 ± 0.0158
DAY 85/ -15 min (n=216, 208)0.090 ± 0.0160-0.022 ± 0.0162
DAY 85/ 5 min (n=221, 214)0.118 ± 0.0161-0.018 ± 0.0163
DAY 85/ 15 min (n=222, 216)0.171 ± 0.0164-0.016 ± 0.0168
DAY 85/ 1h (n=222, 216)0.178 ± 0.0166-0.014 ± 0.0169
DAY 85/ 2h (n=221, 216)0.186 ± 0.01780.006 ± 0.0183
DAY 85/ 4h (n=220, 213)0.147 ± 0.01800.014 ± 0.0182
DAY 85/ 6h (n=221, 214)0.120 ± 0.0183-0.026 ± 0.0183
DAY 85/ 8h (n=220, 214)0.080 ± 0.0180-0.036 ± 0.0181
DAY 85/ 11h 55min (n=216, 207)0.072 ± 0.0165-0.043 ± 0.0165

Adverse events

Non-serious events are listed at a 0.9% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—11/222 (5%)72/222 (32.4%)
Placebo—12/216 (5.6%)66/216 (30.6%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventNVA237Placebo
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders2/2223/216
ANGINA PECTORISCardiac disorders0/2222/216
CORONARY ARTERY DISEASECardiac disorders0/2222/216
ATRIAL FIBRILLATIONCardiac disorders2/2221/216
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/2221/216
CARDIAC ARRESTCardiac disorders0/2221/216
CARDIAC FAILURE CONGESTIVECardiac disorders0/2221/216
VENTRICULAR TACHYCARDIACardiac disorders0/2221/216
PANCREATITISGastrointestinal disorders0/2221/216
BRONCHITISInfections and infestations0/2221/216
Most frequent other events
Showing 10 of 37
Most frequent other events
EventNVA237Placebo
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders22/22226/216
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations8/2226/216
HEADACHENervous system disorders8/2226/216
NASOPHARYNGITISInfections and infestations3/2227/216
COUGHRespiratory, thoracic and mediastinal disorders7/2225/216
UPPER RESPIRATORY TRACT INFECTION BACTERIALInfections and infestations2/2224/216
NASAL CONGESTIONRespiratory, thoracic and mediastinal disorders4/2224/216
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders4/2224/216
ABDOMINAL PAINGastrointestinal disorders0/2223/216
URINARY TRACT INFECTIONInfections and infestations3/2223/216

Baseline characteristics

Age, Continuous
Age, Continuous(years)NVA237PlaceboTotal
Mean62.7 ± 8.3662.1 ± 8.3462.4 ± 8.34
Sex: Female, Male
Sex: Female, Male(Participants)NVA237PlaceboTotal
Female9887185
Male124132256
08

Study locations

54 sites
  • Novartis Investigative Site
    Homewood, Alabama 35209-6870, United States
  • Novartis Investigative Site
    Jasper, Alabama 35501, United States
  • Novartis Investigative Site
    *See Various Dept.'s*, Arizona, United States
  • Novartis Investigative Site
    Tucson, Arizona 85712, United States
  • Novartis Investigative Site
    Fountain Valley, California 92708, United States
  • Novartis Investigative Site
    Fullerton, California 92835, United States
  • Novartis Investigative Site
    Los Angeles, California 90048, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    Riverside, California 92506, United States
  • Novartis Investigative Site
    San Diego, California 92117-4946, United States
  • Novartis Investigative Site
    San Diego, California 92120, United States
  • Novartis Investigative Site
    Brandon, Florida 33511, United States
  • Novartis Investigative Site
    Clearwater, Florida 33756, United States
  • Novartis Investigative Site
    Defuniak Springs, Florida 32435, United States
  • Novartis Investigative Site
    Edgewater, Florida 32132, United States
  • Novartis Investigative Site
    Fort Lauderdale, Florida 33306, United States
  • Novartis Investigative Site
    Hialeah, Florida 33012, United States
  • Novartis Investigative Site
    Miami, Florida 33136, United States
  • Novartis Investigative Site
    Miami, Florida 33156, United States
  • Novartis Investigative Site
    Miami, Florida 33173, United States
  • Novartis Investigative Site
    Miami, Florida 33186, United States
  • Novartis Investigative Site
    Pensacola, Florida 32503, United States
  • Novartis Investigative Site
    Pompano Beach, Florida 33060, United States
  • Novartis Investigative Site
    Port Orange, Florida 32127, United States
  • Novartis Investigative Site
    Sarasota, Florida 34233, United States
  • Novartis Investigative Site
    South Miami, Florida 33143, United States
  • Novartis Investigative Site
    Summerfield, Florida 34491, United States
  • Novartis Investigative Site
    Tamarac, Florida 33321, United States
  • Novartis Investigative Site
    Tampa, Florida 33603, United States
  • Novartis Investigative Site
    Winter Park, Florida 32789, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89104, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89123, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28207, United States
  • Novartis Investigative Site
    Raleigh, North Carolina 27607, United States
  • Novartis Investigative Site
    Shelby, North Carolina 28152, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29406-7108, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29407, United States
  • Novartis Investigative Site
    Columbia, South Carolina 29201, United States
  • Novartis Investigative Site
    Easley, South Carolina 29640, United States
  • Novartis Investigative Site
    Gaffney, South Carolina 29340, United States
  • Novartis Investigative Site
    Greenville, South Carolina 29615, United States
  • Novartis Investigative Site
    Ninety Six, South Carolina 29666, United States
  • Novartis Investigative Site
    Rock Hll, South Carolina 29732, United States
  • Novartis Investigative Site
    Seneca, South Carolina 29678, United States
  • Novartis Investigative Site
    Simpsonville, South Carolina 29681, United States
  • Novartis Investigative Site
    Spartanburg, South Carolina 29303, United States
  • Novartis Investigative Site
    Union, South Carolina 29379, United States
  • Novartis Investigative Site
    Amarillo, Texas 79106-4165, United States
  • Novartis Investigative Site
    Arlington, Texas 76012, United States
  • Novartis Investigative Site
    Arlington, Texas 76014, United States
  • Novartis Investigative Site
    Beaumont, Texas 77701, United States
  • Novartis Investigative Site
    Dallas, Texas 75251, United States
  • Novartis Investigative Site
    Huntsville, Texas 77340, United States
  • Novartis Investigative Site
    Waco, Texas 76712, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2012
First posted
Oct 18, 2012
Start
Nov 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Feb 12, 2015
Last update
Mar 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01709864
Responsible party
Sponsor
First posted
Oct 18, 2012
Start date
Nov 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Feb 12, 2015
Last update
Mar 4, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion